Opinion|Videos|December 12, 2025
Adherence and Persistence
Panelists discuss how improving adherence to LDL-lowering therapies is essential for sustained cardiovascular protection.
Advertisement
Episodes in this series
Panelists discuss how adherence to low-density lipoprotein (LDL)–lowering therapy, particularly injectables, remains one of the greatest challenges to long-term success. Patients often discontinue treatment due to side effects, inconvenience, or lack of follow-up support.
Pharmacists and health systems can play a key role in monitoring persistence, providing reminders, and counseling patients about the benefits of sustained therapy.
Panelists emphasize that simplifying treatment regimens and enhancing digital engagement could improve adherence and outcomes.
Advertisement
Related to this article
Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.
Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.
Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Advertisement
Advertisement
Trending on AJMC
1
First-Line Vitiligo Treatment: Topical JAK Inhibitors and Phototherapy
2
Precision Drugs Meet Payer Realities
3
Cleveland Clinicians Say Obesity Care Starts Too Late for Many Patients
4
GOLD COPD Conference Turns to Earlier Diagnosis and Proactive Care
5